Form 4: Hologic CFO Karleen Oberton Reports Stock Transaction

Hologic's Chief Financial Officer, Karleen Oberton, disposed of 1,332 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Karleen Oberton, the Chief Financial Officer of Hologic Inc., reported a transaction involving the company's common stock.
• On November 14, 2024, Ms. Oberton disposed of 1,332 shares of Hologic common stock.
• The shares were sold at a price of $77.54 per share.
• This transaction was to cover tax obligations related to the settlement of restricted stock units.
• Following the transaction, Ms. Oberton beneficially owns 102,108 shares of Hologic common stock, which includes 41,121 restricted stock units/performance stock units with deferred settlement.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an insider stock transaction, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider transactions and is common for executives who receive equity compensation. It does not indicate any specific trend in the medical device industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, such as Hologic, and are required by the SEC to ensure transparency in insider trading.
• Similar filings are made by executives at comparable companies like Abbott Laboratories (ABT) and Medtronic (MDT) when they engage in stock transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale of shares by an executive for tax purposes.

Key Dates

Keywords

Hologic, Karleen Oberton, stock transaction, Form 4, insider trading, restricted stock units, tax obligations, equity compensation